Updated from 2:24 p.m. ESTShares of Hospira ( HSP) were among the worst-performing health-related stocks Monday. The stock fell 8.2% after the company trimmed its 2005 earnings and sales forecast, warning that results would fall below consensus estimates. Excluding items, the hospital-products maker expects to post a profit of $1.53 to $1.60 a share on sales of about $2.5 billion. Analysts polled by Thomson First Call had been expecting earnings of $1.76 a share on sales of $2.62 billion. In November, the company predicted that it would post adjusted earnings of $1.65 to $1.70 a share on sales of $2.6 billion. Shares traded down $2.59 to $28.89. Despite posting second-quarter results that topped expectations as well as raising 2005 estimates, Accredo Health fell modestly on Monday. The pharmacy-services company earned $20.2 million, or 41 cents a share, on sales of $503.9 million during the second quarter. Analysts were expecting earnings of 40 cents a share on sales of $488.5 million. A year ago the company earned $19.9 million, or 41 cents a share, on sales of $389.8 million. Looking ahead, Accredo raised its 2005 earnings forecast to $1.56 to $1.61 a share, up from previous guidance of $1.53 to $1.60 a share. Sales are expected to be $1.85 billion to $1.9 billion. Analysts are expecting earnings of $1.61 a share on sales of $1.88 billion. Shares traded down 20 cents to $29.78. Shares of Haemonetics ( HAE - Get Report) rose 6.6% after the maker of blood-processing systems posted third-quarter earnings and sales above expectations. The company earned $11 million, or 42 cents a share, on sales of $98.1 million. Analysts were expecting earnings of 37 cents a share on sales of $94.3 million. The company's blood-bank disposables segment jumped to $34 million in sales, up 14.8% vs. a year ago, which helped offset a 9.4% decline in the company's plasma-disposables segment. Shares traded up $2.41 to $38.87.
Wyeth fell 7.8% after the company posted fourth-quarter earnings and sales that fell below expectations and warned that 2005 earnings would fall below expectations as well. Excluding legal items associated with the recall of its fen-phen diet drugs, the company earned 64 cents a share on sales of $4.65 billion. Analysts were expecting earnings of 67 cents a share on sales of $4.66 billion. Looking ahead, Wyeth forecast 2005 earnings of $2.70 to $2.80 a share. Analysts had been expecting earnings of $2.89 a share. Shares traded down $3.35 to $39.63. Other health care movers included Pfizer ( PFE - Get Report), down 19 cents to $24.16; Merck ( MRK - Get Report), up 3 cents to $28.05; Aastrom Biosciences ( ASTM), up 18 cents to $3.37; StemCells ( STEM), up 3 cents to $4.91; Johnson & Johnson ( JNJ), up 8 cents to $64.70; and Schering-Plough , down 31 cents to $18.56.